(RTTNews) - Century Therapeutics, Inc. (IPSC), a biotechnology company, on Tuesday, announced the initiation of an investigator-initiated Phase 1/2 clinical trial for its iPSC-derived NK cell therapy, CNTY-101, in patients with B-cell mediated autoimmune diseases.
The trial, sponsored by the Friedrich-Alexander University Erlangen-Nürnberg and led by Professors Georg Schett and Andreas Mackensen, will evaluate CNTY-101 in conditions including systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis.
The trial, named CARAMEL, will focus on evaluating the safety, efficacy, and translational data of CNTY-101 in several autoimmune diseases, with the study expected to start in mid-2025.
Brent Pfeiffenberger, CEO of Century Therapeutics, stated, "We're excited to see CNTY-101 evaluated by these leading experts, which reflects the promising potential of our iPSC-derived cell therapies in autoimmune diseases. We look forward to seeing the trial's impact."
Dr. Andreas Mackensen from Friedrich-Alexander University highlighted the advantages of CNTY-101, saying, "This off-the-shelf therapy eliminates logistical barriers and has the potential to treat autoimmune diseases in outpatient settings."
The CARAMEL trial adds to Century's broader development program, which also includes the ongoing CALiPSO-1 trial in cancer. Century aims to expand its research in autoimmune diseases and bring new treatments to patients with limited options.
Century is also planning to expand its CALiPSO-1 trial to European sites and will provide updates as patient enrollment progresses.
Cash position:
The company had a cash, cash equivalents, and marketable securities were $244.7 million as of September 30, 2024.
IPSC shares debuted on the Nasdaqglobal marketon June 18, 2021, under the ticker symbol "IPSC", priced at $20.00 per share.
IPSC closed Friday's (Jan.17 2025) trading at $0.90 up 0.45%. In premarket trading Tuesday, the stock is up 5.58% at $0.96.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Earns%20%242.3B%20From%20BR%20Distribuidora%20Stake%20Sale%20%7C%20Nasdaq&_biz_n=21&rnd=317883&cdn_o=a&_biz_z=1743333204424)
%3F%20%7C%20Nasdaq&_biz_n=22&rnd=794147&cdn_o=a&_biz_z=1743333204425)
